Tango Therapeutics accounting officer sells 8,200 shares

The principal accounting officer's three sales were made under a Rule 10b5-1 plan adopted June 23, 2026.

Rhea-AI Filing Summary

Tango Therapeutics, Inc. Principal Accounting Officer Jessica Newcomb sold 8,200 shares of common stock on September 22, 2026, in three transactions: 700 shares at a weighted-average $22.8029 per share, 5,100 at $23.9683, and 2,400 at $25.1718. The sales were made under a Rule 10b5-1 trading plan adopted June 23, 2026. The reported amount owned following the transactions included 43,666 unvested RSUs, each a contingent right to receive one common share.

Insider Trade Summary 10b5-1

Net Seller: 8,200 shares

Net Sell 3 txns

Insider Newcomb Jessica

Role Principal Accounting Officer

Sold 8,200 shs ($199K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	700	$22.8029	$16K
Sale	Common Stock F1, F4, F3	5,100	$23.9683	$122K
Sale	Common Stock F1, F5, F3	2,400	$25.1718	$60K

Holdings After Transaction: Common Stock — 59,121 shares (Direct)

Footnotes (5)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.
2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.37 to $23.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. F3. The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $23.52 to $24.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $24.59 to $25.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Figures

Common shares sold: 8,200 shares Shares sold—transaction 1: 700 shares Weighted-average sale price—transaction 1: $22.8029 per share +5 more

8 metrics

Common shares sold 8,200 shares Across three sales on September 22, 2026

Shares sold—transaction 1 700 shares September 22, 2026

Weighted-average sale price—transaction 1 $22.8029 per share September 22, 2026

Shares sold—transaction 2 5,100 shares September 22, 2026

Weighted-average sale price—transaction 2 $23.9683 per share September 22, 2026

Shares sold—transaction 3 2,400 shares September 22, 2026

Weighted-average sale price—transaction 3 $25.1718 per share September 22, 2026

Unvested restricted stock units 43,666 RSUs Included in the reported amount owned following the transactions; each RSU represents a contingent right to one common share

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price per share financial

"Represents the weighted average sales price per share"

restricted stock units financial

"includes 43,666 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNGX shares did Jessica Newcomb sell, and at what prices?

Jessica Newcomb sold 8,200 shares on September 22, 2026, in three transactions: 700 shares at a weighted-average $22.8029 per share, 5,100 at $23.9683, and 2,400 at $25.1718. The sales were made under a Rule 10b5-1 trading plan adopted June 23, 2026.

What price ranges were reported for Jessica Newcomb's TNGX sales?

The 700-share sale had a weighted-average price of $22.8029, with shares sold from $22.37 to $23.32. The 5,100-share sale averaged $23.9683, with shares sold from $23.52 to $24.41. The 2,400-share sale averaged $25.1718, with shares sold from $24.59 to $25.56.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 07:42 PM Accepted by SEC EDGAR 09/24/2026 - 07:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newcomb Jessica

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		S(1)		700	D	$22.8029(2)	66,621(3)	D
Common Stock	09/22/2026		S(1)		5,100	D	$23.9683(4)	61,521(3)	D
Common Stock	09/22/2026		S(1)		2,400	D	$25.1718(5)	59,121(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.37 to $23.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $23.52 to $24.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Represents the weighted average sales price per share. The shares sold at prices ranging from $24.59 to $25.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	/s/ Julie Fogarty, as attorney-in-fact	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)